Andere Sprachen Innoviva, Inc.

Aktien

A2AC9U

US45781M1018

INVA

Pharmazeutika

Realtime-Estimate Cboe BZX Andere Börsenplätze 17:38:18 12.12.2025			% 5 Tage	Veränd. 1. Jan.
20.60 ^USD	-0.10%		+0.02%	+19.57%

13.11.	Beacon Biosignals sammelt 86 Millionen US-Dollar zur Beschleunigung KI-gestützter Erkenntnisse über die Gehirngesundheit ein	RE
05.11.	Innoviva, Inc. kündigt Aktienrückkaufprogramm im Wert von 125 Millionen US-Dollar an	CI

Andere Sprachen

Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea	00:36
Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference	25.11.
Beacon Biosignals raises $86 million to accelerate AI-driven insights into brain health	13.11.
Beacon Biosignals, Inc. announced that it has received $86 million in funding from a group of investors	12.11.
Innoviva: Q3 Earnings Snapshot	05.11.
Innoviva Q3 revenue up 20%, net income surges	05.11.
Earnings Flash (INVA) Innoviva, Inc. Reports Q3 Revenue $107.8M, vs. FactSet Est of $91.4M	05.11.
Innoviva, Inc. announces an Equity Buyback for $125 million worth of its shares.	05.11.
Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress	05.11.
Innoviva, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	05.11.
Innoviva, Inc. authorizes a Buyback Plan.	05.11.
Antheia appoints Eric d'Esparbes as chief financial officer	21.10.
Antheia Appoints Eric d'Esparbes as Chief Financial Officer	21.10.
Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025	20.10.
Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025	07.10.
Beacon Biosignals, Inc. announced that it expects to receive $98.97489 million in funding	01.10.
Innoviva to Participate in Upcoming Investor Conferences	26.08.
Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award	13.08.
Innoviva's Specialty Therapeutics, Royalty Portfolio to Drive Outperformance, Oppenheimer Says	11.08.
Innoviva: Q2 Earnings Snapshot	06.08.
Healthcare firm Innoviva posts Q2 net income	06.08.
Earnings Flash (INVA) Innoviva, Inc. Reports Q2 Revenue $100.3M, vs. FactSet Est of $92.0M	06.08.
Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress	06.08.
Innoviva, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	06.08.
Innoviva Says FDA Grants Priority Review to Zoliflodacin NDA for Treating Gonorrhea; Shares Up Pre-Bell	12.06.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Innoviva, Inc.

Aktien

A2AC9U

US45781M1018

INVA

Pharmazeutika

Andere Sprachen

Filter